Phase II trials of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer Journal Article
| Authors: | Krug, L. M.; Miller, V. A. |
| Article Title: | Phase II trials of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer |
| Abstract: | Both vinorelbine and docetaxel are effective as single agents in non- small cell lung cancer, with response rates of 25% to 30%. Several in vitro and in vivo models demonstrate schedule-dependent synergy between these agents. In phase II clinical trials of the combination, response rates and median survivals ranged from 27% to 49% and 5 to 9 months, respectively. Common toxicities included neutropenia, febrile neutropenia, and mucositis. With prolonged therapy, severe onycholysis and eye irritation also have been noted. In conclusion, docetaxel and vinorelbine are active together and offer one alternative to cisplatin-based therapy for patients with adequate performance status. |
| Keywords: | cancer survival; human tissue; survival analysis; human cell; major clinical study; clinical trial; neutropenia; advanced cancer; dose response; paclitaxel; phase 2 clinical trial; lung non small cell cancer; mucosa inflammation; antineoplastic combined chemotherapy protocols; carcinoma, non-small-cell lung; lung neoplasms; vinblastine; docetaxel; disease severity; taxoids; phase 1 clinical trial; navelbine; recombinant granulocyte colony stimulating factor; meta analysis; onycholysis; lacrimation; clinical trials, phase ii; humans; human; priority journal; article |
| Journal Title: | Seminars in Oncology |
| Volume: | 26 |
| Issue: | 5 Suppl. 16 |
| ISSN: | 0093-7754 |
| Publisher: | Elsevier Inc. |
| Date Published: | 1999-10-01 |
| Start Page: | 24 |
| End Page: | 26 |
| Language: | English |
| PUBMED: | 10585005 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 16 August 2016 -- Source: Scopus |
